Form 4: ResMed Director Nicole Mowad-Nassar Awarded 241 RSUs

ResMed Inc. Director Nicole Mowad-Nassar was granted 241 restricted stock units, scheduled to vest one year from the grant date.

Summary

• Nicole Mowad-Nassar, a Director of ResMed Inc. (RMD), was granted 241 shares of ResMed Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant is September 2, 2025.
• The acquisition price for these RSUs was $0 per share, which is typical for equity grants.
• Following this transaction, Ms. Mowad-Nassar beneficially owns 241 shares directly.
• The RSUs are scheduled to vest on the first anniversary of the grant date, which will be September 2, 2026.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a standard compensation practice. It is generally viewed as neutral to slightly positive as it aligns insider interests with shareholders, but does not contain information that would significantly alter the company's financial outlook or investment thesis.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of the shareholders, encouraging long-term performance.
• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to insider equity transactions.

Future Outlook

The 241 Restricted Stock Units granted to Director Nicole Mowad-Nassar are scheduled to vest on September 2, 2026, which is the first anniversary of the grant date.

Industry Context

The grant of Restricted Stock Units to a director is a common practice in the medical device and healthcare technology industry, serving as a form of long-term incentive compensation to align executive and director interests with shareholder value creation.

Comparison to Industry Standards

• Equity grants, particularly Restricted Stock Units (RSUs), are a standard component of director compensation packages across publicly traded companies, including those in the healthcare sector like Medtronic, Philips, and Stryker.
• The grant of 241 units, with a $0 acquisition price and a one-year vesting schedule, is consistent with typical RSU awards designed to retain talent and incentivize performance over a defined period.

Related Party Transactions

• The grant of 241 Restricted Stock Units to Nicole Mowad-Nassar, a director of ResMed Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units are scheduled to vest on September 2, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice. It does not contain information that would significantly alter the investment thesis for ResMed Inc. A 'hold' recommendation reflects that this disclosure alone does not warrant a change in an existing position, as it is a standard operational event rather than a material change in company fundamentals or outlook.

Keywords

ResMed, RMD, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Mowad-Nassar Nicole, Insider Transaction